Al Kasab Sami, Lynn Michael J, Turan Tanya N, Derdeyn Colin P, Fiorella David, Lane Bethany F, Janis L Scott, Chimowitz Marc I
Department of Neurology, Medical University of South Carolina, Charleston, South Carolina.
Department of Biostatistics and Bioinformatics, Emory University Rollins School of Public, Health, Atlanta, Georgia.
J Stroke Cerebrovasc Dis. 2017 Jan;26(1):108-115. doi: 10.1016/j.jstrokecerebrovasdis.2016.08.038. Epub 2016 Oct 17.
An American Heart Association/American Stroke Association (AHA/ASA) writing committee has recently recommended that tissue evidence of cerebral infarction associated with temporary symptoms (CITS) lasting <24 hours should be considered a stroke. We analyzed the impact of considering CITS as equivalent to stroke on the results of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.
We compared outcomes in the medical (n = 227) and stenting (n = 224) groups in SAMMPRIS using the following primary end point (new components in bold): any stroke, CITS, or death within 30 days after enrollment or within 30 days after a revascularization procedure for the qualifying lesion during follow-up; or ischemic stroke or CITS in the territory of the qualifying artery beyond 30 days. We also compared the use of brain magnetic resonance imaging (MRI) after transient ischemic attacks (TIAs) in both treatment groups.
By considering CITS as equivalent to stroke, the number of primary end points increased from 34 to 43 in the medical group and from 52 to 66 in the stenting group of SAMMPRIS. The Kaplan-Meier curves for the primary end points in the 2 groups were significantly different (P = .009). The percentage of patients with reported TIAs who underwent brain MRI was 69% in the medical group and 61% in the stenting group (P = .40).
Using the AHA/ASA definition of stroke resulted in a substantially higher primary end point rate in both treatment groups and an even higher benefit from medical therapy over stenting than originally shown in SAMMPRIS. The higher rate of CITS in the stenting group was not due to ascertainment bias.
美国心脏协会/美国卒中协会(AHA/ASA)写作委员会最近建议,与持续时间<24小时的短暂症状相关的脑梗死组织证据(CITS)应被视为卒中。我们分析了将CITS等同于卒中对颅内狭窄患者预防复发性卒中的支架置入和积极药物治疗(SAMMPRIS)试验结果的影响。
我们比较了SAMMPRIS试验中药物治疗组(n = 227)和支架置入组(n = 224)的结局,使用以下主要终点(加粗为新增部分):入组后30天内或随访期间针对合格病变进行血管重建手术后30天内发生的任何卒中、CITS或死亡;或30天后在合格动脉供血区域发生的缺血性卒中和CITS。我们还比较了两个治疗组中短暂性脑缺血发作(TIA)后脑部磁共振成像(MRI)的使用情况。
将CITS等同于卒中后,SAMMPRIS试验中药物治疗组的主要终点数量从34增加到43,支架置入组从52增加到66。两组主要终点的Kaplan-Meier曲线有显著差异(P = .009)。报告有TIA的患者中接受脑部MRI检查的比例,药物治疗组为69%,支架置入组为61%(P = .40)。
采用AHA/ASA的卒中定义导致两个治疗组的主要终点发生率大幅提高,且药物治疗相对于支架置入的获益比SAMMPRIS试验最初显示的更高。支架置入组中CITS发生率较高并非由于确诊偏倚。